Sampatrilat

• CAT Number: M111712
• CAS Number: 129981-36-8
• Molecular Formula: C26H40N4O9S
• Molecular Weight: 584.68
• Purity: ≥95%
• Synonyms: (2S)-2-[[[(2S)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid
• InChI: InChI=1S/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)22(32)28-16-18(23(33)34)15-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,32)(H,29,37)(H,33,34)(H,35,36)/t18-,20-,21-/m0/s1
• InChIKey: LPUDGHQMOAHMMF-JBACZVJFSA-N
• SMILES: CS(=O)(=O)NC(CCCCN)C(=O)NCC(CC1(CCCC1)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)O)C(=O)O

Sampatrilat（Cat No.:M111712）is a potent inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP), offering dual-action benefits in cardiovascular therapy. It effectively lowers blood pressure and mitigates heart failure symptoms by inhibiting the enzymes responsible for vasoconstriction and fluid retention. Sampatrilat’s unique mechanism promotes vasodilation and sodium excretion, improving overall cardiovascular health. Its therapeutic potential extends to treating hypertension, chronic heart failure, and related disorders, making it a promising candidate in advanced cardiovascular treatment regimens. Its efficacy and multifunctionality position Sampatrilat as a key player in cardiovascular pharmacology.